A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women.
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2011
At a glance
- Drugs Romosozumab (Primary)
- Indications Fracture; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 03 Feb 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 03 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.